NCT01449799 - An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2011

Primary Completion Date

September 21, 2011

Study Completion Date

September 21, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK961081 800 microgram dose

To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers

DRUG

Fluticasone Propionate 500 microgram dose

To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers

DRUG

GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately

To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation

DRUG

GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend

To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London